Delvaux M, Wingate D
Gastroenterology Unit, CHU Rangueil, Toulouse, France.
J Int Med Res. 1997 Sep-Oct;25(5):225-46. doi: 10.1177/030006059702500501.
The actions of trimebutine [3,4,5-trimethoxybenzoic acid 2-(dimethylamino)-2-phenylbutylester] on the gastrointestinal tract are mediated via (i) an agonist effect on peripheral mu, kappa and delta opiate receptors and (ii) release of gastrointestinal peptides such as motilin and modulation of the release of other peptides, including vasoactive intestinal peptide, gastrin and glucagon. Trimebutine accelerates gastric emptying, induces premature phase III of the migrating motor complex in the intestine and modulates the contractile activity of the colon. Recently, trimebutine has also been shown to decrease reflexes induced by distension of the gut lumen in animals and it may therefore modulate visceral sensitivity. Clinically, trimebutine has proved to be effective in the treatment of both acute and chronic abdominal pain in patients with functional bowel disorders, especially irritable bowel syndrome, at doses ranging from 300 to 600 mg/day. It is also effective in children presenting with abdominal pain.
曲美布汀[3,4,5-三甲氧基苯甲酸2-(二甲基氨基)-2-苯基丁酯]对胃肠道的作用是通过以下方式介导的：(i) 对外周μ、κ和δ阿片受体的激动作用；(ii) 释放胃肠肽，如胃动素，并调节其他肽的释放，包括血管活性肠肽、胃泌素和胰高血糖素。曲美布汀可加速胃排空，诱导肠道移行性运动复合波的早熟Ⅲ期，并调节结肠的收缩活动。最近，曲美布汀还被证明可减少动物肠道管腔扩张引起的反射，因此它可能调节内脏敏感性。临床上，已证明曲美布汀在治疗功能性肠病患者的急性和慢性腹痛方面有效，尤其是肠易激综合征，剂量范围为每日300至600毫克。它对出现腹痛的儿童也有效。
